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Abstract:  The db/db mouse is one of the diabetes mellitus animal models and if the pathophysiological stages of
diabetic changes in the mouse model could simulate the stages in human diabetes, the db/db mouse could be used to
better evaluate drug candidates.  Blood insulin, HbA1c levels and morphological features of pancreatic islets in db/db
mice were evaluated to determine the pathophysiological stage.  At 6 weeks of age, db/db mice showed the highest level
of plasma insulin and lowest level of HbA1c, and histopathological examination revealed enlarged islets with a circular
shape and hypertrophic islet cells.  By 9 and 12 weeks of age, the plasma insulin levels had decreased to mid levels and
HbA1c had increased to mid to high levels; histopathological examination at this time revealed two types of islets
coexisting, enlarged circular islets and small irregular-shaped islets.  By 15 and 22 weeks of age, plasma insulin had
decreased further to low levels and HbA1c was at its highest level; the histopathological examination at this time
revealed an increase in irregular-shaped and small islets.  Based on blood insulin levels, HbA1c levels and
histopathology findings in the db/db mice in this study, the clinical staging of diabetic changes were recognized.  The
pathophysiological stages of diabetes mellitus in this animal model were similar to the stages in humans.  (J Toxicol
Pathol 2009; 22: 133–137)
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Introduction
Diabetes mellitus is clinically classified into three
stages based on the degree of insulin dependence.  The
stages are non-insulin requiring (NIR), insulin requiring for
control of blood glucose (IRC) and insulin requiring for
survival (IRS)1–4.  A patients’ pharmacologic treatment is
selected based on these stages because combinations of
different oral agents may be useful for controlling
hyperglycemia before insulin therapy becomes necessary3, 5.
At the NIR stage, adequate glycemic control can be achieved
through weight reduction, exercise and/or oral glucose-
lowering agents, and so individuals at this stage do not
require insulin.  Individuals at the IRC stage have some
residual insulin secretion, but require exogenous insulin for
adequate glycemic control, and can also survive without
taking insulin.  Individuals at the IRS stage with extensive β-
cell destruction and therefore no residual insulin secretion
require insulin for survival.
The C57BL/KsL db/db mouse (db/db mouse) is a
diabetes mellitus animal model that is a spontaneous mutant
strain of the C57BL/KsJ db/db mouse resulting from a point
mutation of the downstream intron of the leptin receptor
gene rendering it unresponsive to leptin6–9.  Leptin is a
peptide hormone secreted by adipocytes and is involved in
eating behavior and energy homeostasis.  So, this animal
models expresses unrepressed eating behavior, becomes
obese and develops severe insulin resistance associated with
hyperinsulinemia and hypertriglyceridemia, followed by
hyperglycemia peaking at 3–4 months of age10.  Pancreatic
islet β-cell mass is reduced as disease progresses, resulting in
severe insufficiency of insulin secretion11–14.  It has also been
well shown by immunohistochemistry that a decrease in
insulin levels of islets of db/db mice occurs at 18 weeks of
age, without referreing to the blood insulin levels, which is
one of the most important biomarkers6.  In spite of the
extensive use of the db/db mouse in this field, there are no
reports on the three clinical stages in the db/db mouse.
However, if pathophysiological staging were possible in the
db/db mouse, drug candidates for diabetes mellitus could be
better evaluated in preclinical studies to selectively target a
specific pathophysiological stage.
In this study, time course blood insulin and
glycosylated hemoglobin (HbA1c) levels, the clinical
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parameters for evaluation of the pathophysiological stages of
diabetes mellitus in humans3, 15, and morphological features
of pancreatic islets in db/db mice were examined in order to
determine the pathophysiological stage of the disease in the
diabetic mouse model.  Both the American Diabetes
Association (ADA) and the American Association of
Clinical Endocrinologists (AACE) recommend monitoring
glycemic control using HbA1c as the parameter15–18.  The
major advantage of measuring HbA1c is that a specimen can
be collected without regard to when the patient last ate19.
Materials and Methods
Animals
Twenty five male db/db mice were purchased from
Charles River Laboratories (Japan) and subjected to
experimentation at 5 weeks of age.  The animals were
housed in cages in an animal room maintained at a
temperature of 23 ± 2°C and a humidity of 55 ± 10%, with 14
to 16 air changes per hour and a 14-hour light and 10-hour
dark cycle.  The animals were given pelleted chow (CE-2;
Clea Japan, Inc., Tokyo, Japan) and tap water ad libitum.  All
animal procedures were conducted in accordance with
Chugai Pharmaceutical’s Guide for the Care and Use of
Laboratory Animals, and all experimental protocols were
approved by the Institutional Animal Care and Use
Committee.
Experimental design
The db/db mice were divided into 5 groups (n=5 per
group), and the animals of each group were sacrificed by
exsanguination under ether anesthesia at the age of 6, 9, 12,
15 or 22 weeks after their body weights were measured and
blood samples were collected.  Blood samples were obtained
from the caudal vena cava for measurement of plasma
insulin and HbA1c.
Plasma insulin levels were measured using ELISA
(Institute of Biological Science, Inc., Yokohama, Japan), and
the percentage of HbA1c was measured using an auto
analyzer (Type 7170, Hitachi High-Technologies
Corporation, Tokyo, Japan).  The pancreas was removed
from all necropsied animals, fixed in 20% neutral buffer
formalin solution, embedded in paraffin wholly, sectioned
longitudinally and stained with hematoxylin and eosin.
Histopathological evaluation of pancreatic islets was
performed under light microscopy. 
Results
At 6 weeks of age, the mean body weight was 33.67 ±
0.39 g, the level of the plasma insulin was at its highest
(16.82 ± 1.03 ng/mL) and the level of HbA1c was at its
lowest (2.06 ± 0.14%) during the observation period (Fig. 1).
Histopathological examination revealed enlarged, circular-
shaped islets, which were consistent with hypertrophic islet
cells having abundant cytoplasm and a large vacuole with a
curved lucent region considered to be the Golgi apparatus20
(Fig. 2a).
At 9 and 12 weeks  of age, the mean body weights were
45.13 g ± 1.50 and 47.93 g ± 4.14, respectively.  The level of
plasma insulin had decreased to mid levels (8.92 ± 2.14 ng/
mL and 7.73 ± 2.61 ng/mL, respectively), and the level of
HbA1c had increased to middle to high mean levels (5.79 ±
0.54% and 10.11 ± 0.84%; Fig. 1).  In the histopathological
examination, two types of islets were coexisting: enlarged
islets similar to those observed in the 6-week-old animals
(Fig. 2b) and small, irregular-shaped islets consisting of
atrophic islet cells with acinar cells and spindle cells thought
Fig. 1. Time course of changes of body weight (a), plasma
insulin level (b) and HbA1c level (c) in the db/db
mice. Each value represents the mean ± standard
deviation.Yamazaki, Kato, Kato et al. 135
to be myofibroblasts21 (Fig. 2c).
At 15 and 22 weeks of age, the mean body weights were
52.35 ± 4.75 g and 52.37 ± 5.24 g, respectively, the level of
plasma insulin had decreased further to low mean levels
(2.38 ± 0.99 ng/mL and 5.15 ± 0.78 ng/mL, respectively) and
the level of HbA1c had increased to high mean levels (10.47
± 2.06% and 11.21 ± 0.97%; Fig. 1).  Histopathological
examination revealed that the irregular-shaped islets had
decreased further in size.  Islet cells were even more atrophic
than in the 12-week-old animals, and the presence of acinar
cells and spindle cells was obvious (Fig. 2d).
Discussion
Staging of diabetes mellitus is clinically based on
insulin dependence, namely non-insulin requiring (NIR),
insulin requiring for control (IRC) of blood glucose and
insulin requiring for survival (IRS)1–4.  The purpose of this
study was to determine the pathophysiological stage of
diabetes mellitus in db/db mouse at various ages and discuss
the relevance of the stages in the animal model to those in
humans.
In patients at the NIR stage of diabetes mellitus,
adequate glycemic control can be achieved with weight
reduction, exercise and/or oral glucose-lowering agents.
The patients in this stage have insulin secretion ability, and
the glucose level is occasionally high but controllable.  In
this study, the 6-week-old db/db mice can be considered
equivalent to being in the NIR stage of human diabetes
mellitus patients according to the following results: the
animals showed obesity, unlike the nonobese heterozygote
(db/+) mouse6, hypertrophic islet cells were observed in the
histopathological examination and the findings well
reflected blood parameters.  These findings are considered to
Fig. 2. The morphological features of pancreatic islets in db/db mice. Enlarged, circular islet at 6 weeks of age and islet cells with vacuoles (insert,
× 600) (a), enlarged islet at 12 weeks of age (b), small irregular-shaped islet at 12 weeks of age (c) and a smaller and irregular-shaped islet
at 22 weeks of age (d). Short arrows: large vacuoles considered to be Golgi apparatus. Long arrows: acinar cells, Arrowheads: spindle
cells. Magnification: × 400. HE stain. Bar: 50 μm. 136 Segmentation of Diabetic Changes in the db/db Mouse
be an insulin secretion reaction of islet cells caused by
hyperphagia, a characteristic of the db/db mouse6–14.  Based
on the blood parameters of the animals at this stage,
sufficient insulin secreting ability (the highest insulin level)
was preserved to counteract high blood glucose levels.
At the IRC stage in human diabetes mellitus, patients
have some residual insulin secretion but require exogenous
insulin for adequate glycemic control.  The findings in the
db/db models at 9 and 12 weeks of age were equivalent to the
IRC stage.  The animals showed mid-level residual insulin
secretion and mildly increased blood glucose level (mid
levels of HbA1c).  The histopathological findings showed
some irregular-shaped islets, which correlates to the
existence of acinar cells and spindle cells.  It is known that
the fibrotic distraction of islets is commonly observed in
humans and several animal models of type 2 diabetes21.
At 15 and 22 weeks, insulin secretion in the mice was
very low (low levels of insulin), because islets were
destructed (irregular-shaped and small), and the blood
glucose levels had increased (high levels of HbA1c).  In
addition, the decrease of insulin in the islets of db/db mice at
18 weeks of age was shown well in a previous report6, and
the morphology of islet is similar to that in this study.  Our
results indicate that the sustained secretion of insulin
induced β-cell destruction and that the ability to secrete
insulin had almost disappeared.  We consider these findings
to be equivalent to the IRS stage in humans21.
In the db/db mouse used in this study, three distinctive
pathophysiological stages of diabetic change were identified
as shown in Fig. 3.  The results elucidate a time course
relationship between the blood parameters and the
morphology of pancreatic islets in the db/db mouse, where
pathophysiological stages based on plasma insulin levels,
HbA1c levels and histopathological findings are clearly
distinguishable and characteristically reflect the stages of
human diabetes mellitus.  To our knowledge, this is the first
report of a db/db mouse exhibiting pathophysiological stages
similar to those in human diabetes mellitus.  In the
evaluation of new drug candidates for diabetes mellitus,
indicating the time point in the life cycle of the disease
would be very important, as the pharmacologic effects of a
drug must be selected to match patient status3, 5.  In addition,
there is evidence that environmental factors contribute to the
development of obesity and type 2 diabetes22.  Being able to
understand the pathophysiological stage of an animal model
based on blood glucose and insulin would be beneficial.
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